SpyGlass Pharma, Inc. (SGP) — Cash Flow-to-Debt Ratio
SpyGlass Pharma, Inc. (SGP) has a Cash Flow-to-Debt Ratio of -0.04x as of December 2025, meaning its operating cash flow of $-9.33 Million could theoretically repay 0% of its total liabilities ($214.70 Million) in one year. See working capital to net assets of SpyGlass Pharma, Inc. to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
SpyGlass Pharma, Inc. Cash Flow-to-Debt Ratio (2023–2025)
Historical debt coverage capacity for SpyGlass Pharma, Inc. across 3 annual periods. Also explore how fast is SpyGlass Pharma, Inc. growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for SpyGlass Pharma, Inc. (2023–2025)
Year-by-year debt coverage analysis for SpyGlass Pharma, Inc.. For market capitalisation and broader financial context, see SpyGlass Pharma, Inc. stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.15x | $-32.70 Million | $214.70 Million | ▲ +42.1% |
| 2024 | -0.26x | $-22.03 Million | $83.79 Million | ▼ -58.7% |
| 2023 | -0.17x | $-12.28 Million | $74.13 Million | — |